Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486341 | 0.86 | AHCY (0.60) | AHCYHIF1ATMEM97SIGMAR1EZH2 | |
| SCHEMBL8362057 | 0.83 | ADORA3 (0.50) | AHCYHIF1ATMEM97SIGMAR1ADORA1 | |
| SCHEMBL536759 | 0.81 | AHCY (0.52) | AHCYHIF1ATMEM97SIGMAR1ADORA1 | |
| SCHEMBL6692383 | 0.81 | AHCY (0.54) | AHCYHIF1ATMEM97SIGMAR1ADORA1 | |
| SCHEMBL1972796 | 0.81 | AHCY (0.63) | AHCYHIF1ATMEM97SIGMAR1PRMT5 | |
| SCHEMBL2780483 | 0.80 | AHCY (0.49) | AHCYPRMT5WDR77ADORA1DOT1L | |
| SCHEMBL940909 | 0.79 | ADORA3 (0.49) | AHCYHIF1ATMEM97SIGMAR1PRMT5 | |
| SCHEMBL674401 | 0.78 | AHCY (0.57) | AHCYHIF1ATMEM97SIGMAR1PRMT5 | |
| SCHEMBL788626 | 0.78 | AHCY (0.57) | AHCYHIF1ATMEM97SIGMAR1PRMT5 | |
| SCHEMBL6445754 | 0.78 | AHCY (0.57) | AHCYHIF1ATMEM97SIGMAR1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732484-B2 | Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-7485655-B2 | 2-Aminothiazole allosteric enhancers of A1 adenosine receptors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1583530-A4 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIV VIRGINIA (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1583530-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1305023-A4 | USE OF SELECTIVE ADENOSINE A1 RECEPTOR AGONISTS, ANTAGONISTS AND ALLOSTERIC ENHANCERS TO MANIPULATE ANGIOGENESIS | UNIV VIRGINIA (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-03 | — | — | US | disclosed |
| US-20030212082-A1 | Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis | VIRGINIA UNIVERSITY OF | 2003-11-13 | — | — | US | disclosed |
| WO-2003061655-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1305023-A1 | USE OF SELECTIVE ADENOSINE A1 RECEPTOR AGONISTS, ANTAGONISTS AND ALLOSTERIC ENHANCERS TO MANIPULATE ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002009701-A1 | USE OF SELECTIVE ADENOSINE A1 RECEPTOR AGONISTS, ANTAGONISTS AND ALLOSTERIC ENHANCERS TO MANIPULATE ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | ADORA1, ADORA2A, ADORA2B | AHCY 713/4885HIF1A 107/4885TMEM97 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.